Last edition
News about "chronic spontaneous urticaria treatment"
CuraTeQ Biologics Announces Positive Phase 3 Results for BP11, Biosimilar to Xolair
CuraTeQ Biologics reports positive Phase 3 results for BP11, a biosimilar to Xolair, meeting primary endpoints in Chronic Spontaneous Urticaria (CSU) studies across Europe and India.
Chronic Spontaneous Urticaria Treatment | 07/04/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members